RESUMEN
WHAT IS KNOWN AND OBJECTIVE: Bullous pemphigoid has been reported in association with gliptins. We describe a case, review the literature and analyse all cases of bullous pemphigoid recorded in the European pharmacovigilance database, EudraVigilance. CASE SUMMARY: A 74-year-old woman, treated with vildagliptin/metformin for 12 months, developed bullous pemphigoid, confirmed by skin biopsy. The symptoms resolved within 7 months after vildagliptin/metformin withdrawal. WHAT IS NEW AND CONCLUSION: A search in EudraVigilance showed a disproportionality for bullous pemphigoid and gliptins, except alogliptin. These findings extend the evidence associating gliptins with this potentially serious disease.
RESUMEN
WHAT IS KNOWN AND OBJECTIVE: To report five cases with a probable interaction between acenocoumarol and levofloxacin. CASE DESCRIPTION: In five patients on long-term acenocoumarol treatment who had had stable international normalized ratios for at least 6 months, sudden erratic changes in the values of these ratios were observed after 1.5-8 days of concomitant levofloxacin treatment with no other apparent cause. WHAT IS NEW AND CONCLUSIONS: Closer monitoring should be considered in patients with concomitant use of acenocoumarol and levofloxacin, especially elderly patients and those with renal dysfunction who seemed to suffer the interaction more severely.
Asunto(s)
Acenocumarol/efectos adversos , Antibacterianos/efectos adversos , Anticoagulantes/efectos adversos , Interacciones Farmacológicas/fisiología , Levofloxacino/efectos adversos , Acenocumarol/uso terapéutico , Anciano de 80 o más Años , Antibacterianos/uso terapéutico , Anticoagulantes/uso terapéutico , Femenino , Humanos , Levofloxacino/uso terapéutico , MasculinoRESUMEN
OBJECTIVES: To evaluate the efficacy and safety of an update to an anti-emetic protocol in chemotherapy for gynecological tumours. METHOD: Prospective observational study performed over 12 months in a general hospital with 400 beds. We evaluated the efficacy of the old anti-emetic protocol, a new protocol was implemented, and its efficacy was determined. We included patients with gynaecological tumours that sought treatment at the Day Hospital. After each chemotherapy cycle, patients filled out a survey that registered the number and severity of episodes of nausea/vomiting and other adverse effects. The efficacy of treatment was measured as complete response (no nausea or vomit) in the acute phase (first 24h after chemotherapy) and late phase (2-5 days after chemotherapy). We also evaluated whether age, the type of protocol, and the emetogenous power of the different treatment schemes could influence patient response. RESULTS: We analysed 102 chemotherapy cycles under the old protocol (52 patients) and 293 cycles under the new protocol (98 patients). We observed significant differences in complete response rates in the late phase between old and new protocols (36.27% vs 67.38%, P<.0001). The probability of obtaining a complete response using the new protocol was twice as high as with the old protocol in acute emesis (OR=1.85, 95% CI: 1.05-3.24, P=.03) and four times higher in late emesis (OR=4.27, 95% CI: 2.59-7.02, P<.0001). CONCLUSIONS: A greater percentage of complete responses to late emesis was obtained using the new protocol. Age and the low emetogenous power of the treatment schemes were predictive factors for complete response in acute emesis.